Physician profile
Stacey B Bean
NPI 1699700674
$2,143.69
in general payments reported to CMS, 2019-2025
31 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.46 · 2020: $81.88 · 2021: $316 · 2022: $362 · 2023: $529 · 2024: $463 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407.06 | 2020-2025 | Qulipta, Lo Loestrin Fe |
| Lilly USA, LLC | $393.92 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $208.53 | 2023-2025 | |
| Novo Nordisk INC | $191.95 | 2022-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $99.77 | 2023-2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $86.22 | 2022-2025 | Wellbutrin, Aplenzin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.42 | 2022 | |
| Glaxosmithkline, LLC. | $61.55 | 2023-2024 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $57.70 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $56.89 | 2022-2025 | Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.13 | 2020-2024 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $50.12 | 2023 | Quviviq |
| Mayne Pharma Commercial LLC | $46.81 | 2023-2025 | |
| Astellas Pharma US INC | $37.33 | 2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $32.01 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $30.67 | 2023 | Krystexxa |
| Abbott Laboratories | $24.92 | 2021 | |
| Allergan, INC. | $24.32 | 2020 | |
| Amgen INC. | $23.25 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.24 | 2022 | |
| Ibsa Pharma INC. | $21.16 | 2022 | |
| Sumitomo Pharma America, INC. | $18.80 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $17.35 | 2025 | Symbravo |
| Bayer Healthcare Pharmaceuticals INC. | $16.06 | 2019 | |
| Currax Pharmaceuticals LLC | $15.69 | 2025 | Contrave |
| Clarus Therapeutics INC. | $15.58 | 2021 | |
| Lupin INC. | $14.29 | 2020 | |
| Merck Sharp & Dohme LLC | $13.46 | 2023 | Pneumovax 23, Gardasil 9, Vaxneuvance |
| Phathom Pharmaceuticals, INC. | $13.37 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $12.97 | 2022 | |
| Irhythm Technologies, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.